시장보고서

상품코드

1507212

세계의 고혈압 치료제 시장, 점유율, 규모, 동향, 산업 분석 리포트 : 병태별, 유형별, 추진제별, 유통 채널별, 약물 유형별, 지역별, 부문별 예측(2024-2023년)

Hypertension Drug Market Share, Size, Trends, Industry Analysis Report, By Condition (Primary, Secondary); By Type; By Propulsion; By Distribution Channel; By Medication Type; By Region; Segment Forecast, 2024- 2023

발행일: 2024년 06월 | 리서치사:

Polaris Market Research | 페이지 정보: 영문 117 Pages | 배송안내 : 1-2일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

Polaris Market Research의 최신 조사에 따르면 세계의 고혈압 치료제 시장 규모는 2032년까지 346억 4,610만 달러에 달할 전망입니다. 이 조사 리포트는 현재 시장 역학에 대한 상세 인사이트와 향후 시장 성장에 관한 분석을 제공하고 있습니다.

고혈압 치료제 시장은 고혈압을 심각한 건강 문제로 인식하는 인식이 높아지고 전 세계에서 의료 서비스에 대한 접근성이 향상됨에 따라 크게 성장하고 있습니다. 이러한 추세는 항고혈압제 수요를 자극하는 데 매우 중요합니다. 고혈압에 대한 인식 개선과 의료 접근성 향상은 심혈관 질환의 주요 위험 요소인 고혈압의 진단과 관리에 직접적인 영향을 미치기 때문입니다.

고혈압(흔히 고혈압이라고도 함)에 대한 인식이 일반 대중과 의료 종사자들 사이에서 크게 증가하고 있습니다. 이러한 인식 증가는 심혈관 질환을 퇴치하기 위한 정부 및 비정부기구의 광범위한 공중보건 캠페인, 교육 프로그램 및 구상의 결과입니다. 이러한 노력은 뇌졸중, 심장마비, 신부전 등 고혈압과 관련된 위험에 대한 인식을 높이고 혈압을 적극적으로 관리할 수 있도록 장려하고 있습니다. 이러한 인식이 높아짐에 따라 더 많은 사람들이 고혈압 진단을 받고, 이는 항고혈압제 수요에 직접적인 영향을 미칠 수 있습니다.

고혈압 치료제 시장을 촉진하는 헬스케어 접근성의 역할은 아무리 강조해도 지나치지 않습니다. 최근 전 세계에서, 특히 개발도상국을 중심으로 의료 인프라 구축이 활발히 진행되고 있습니다. 여기에는 의료 시설의 확대, 의료 종사자 증가, 보편적 의료보험제도 도입 등이 포함됩니다. 이러한 발전은 더 많은 사람들이 더 쉽게 의료 서비스를 이용할 수 있게 하고, 고혈압 진단과 치료의 가능성을 높여주고 있습니다. 고혈압을 조기에 효과적으로 관리하면 심각한 합병증과 항고혈압제 사용의 필요성을 초래하는 심각한 합병증 발생 위험을 크게 줄일 수 있습니다.

원격의료와 디지털 헬스 플랫폼도 의료 접근성을 강화하는 데 있으며, 매우 중요한 역할을 하고 있습니다. 이러한 기술을 통해 원격지나 의료 서비스가 부족한 지역의 환자들도 의료진과 상담하고, 건강 교육을 받고, 고혈압과 같은 만성질환을 관리할 수 있게 되었습니다. 원격의료 서비스의 편리함과 효율성으로 인해 이러한 플랫폼이 널리 채택되어 더 많은 환자들이 적시에 진단과 처방을 받을 수 있게 되면서 고혈압 치료제에 대한 수요가 더욱 증가하고 있습니다.

또한 고혈압 관리가 1차의료 환경에 통합된 것은 의료 접근성을 개선하는 데 중요한 요소로 작용하고 있습니다. 1차 진료의는 건강상 우려를 가진 사람들이 가장 먼저 접촉하는 곳이기 때문에 고혈압을 조기에 발견하고 관리하는 데 도움이 될 수 있습니다. 정기 검진에 혈압 검진을 포함시킴으로써 의료 시스템은 고혈압을 보다 효과적으로 식별하고 치료할 수 있습니다.

고혈압의 세계적 부담은 공중보건의 시급한 과제이며, 이 질환은 전 세계 질병 부담의 주요 원인이 되고 있습니다. 사회가 혈압이 조절되지 않는 것이 무엇을 의미하는지 더 많이 알게 되고, 의료 시스템이 더 종합적이고 접근하기 쉬운 시스템으로 진화함에 따라 고혈압 치료제에 대한 수요가 증가할 것으로 예상됩니다. 예방적 건강관리와 만성질환 관리에 대한 관심이 높아지면서 효과적인 항고혈압제에 대한 필요성이 더욱 커지고 있습니다.

고혈압 치료제 시장 보고서 하이라이트

2023년 안지오텐신 전환효소(A.C.E.) 억제제 부문은 고혈압 치료제 시장에서 가장 큰 시장 점유율을 차지할 것으로 예상됩니다. A.C.E. 억제제는 심각한 부작용 없이 장기적인 고혈압 관리에 효과적이기 때문에 만성 치료제로 선호되고 있습니다.

소매 약국 부문은 예측 기간 중 가장 빠른 CAGR로 성장할 것으로 예상됩니다. 소매 약국은 혈압 모니터링, 건강 검진, 만성질환 관리 프로그램 등의 서비스를 제공하는 경우가 증가하면서 고혈압 환자들에게 중요한 접점이 되고 있습니다.

2023년 북미가 가장 큰 시장을 차지했습니다. 북미의 고령화는 고혈압 치료제 시장에 큰 기여를 하고 있습니다. 고혈압 유병률은 연령에 따라 증가하며, 미국 인구 조사국은 2030년까지 베이비붐 세대가 모두 65세 이상이 될 것으로 예상하고 있으며, 고혈압 치료제에 대한 수요가 더욱 증가할 것으로 예상하고 있습니다.

아시아태평양은 고혈압 치료제 시장에서 가장 빠른 CAGR로 성장할 것으로 예상됩니다. 경제 성장과 의료비 지출 증가: 많은 아시아태평양 국가에서 경제 성장으로 인해 의료비 지출이 증가하고 있습니다. 이로 인해 의료 인프라에 대한 투자가 확대되어 고혈압 치료제를 포함한 다양한 의약품에 대한 접근성이 향상되고 있습니다.

세계의 주요 시장 기업은 Takeda Pharmaceutical Company Limited., AstraZeneca, Teva Pharmaceutical Industries Ltd, Abbott, Pfizer Inc., Novartis AG, Merck KGaA, Johnson & Johnson Services, Inc., Gilead Sciences, Inc., Sanofi S.A., Bayer AG. 등입니다.

고혈압 치료제 - 업계 스냅숏
고혈압 치료제 시장 역학
- 촉진요인과 기회
  - 전 세계에서 고혈압증의 이환율이 증가하고 있으며, 약제 수요가 증가할 것으로 예측된다.
  - 고혈압이 중대한 건강 문제라는 인식의 향상과 헬스케어 서비스에 대한 액세스의 개선
- 억제요인과 과제
  - 특허 유효기간
PESTLE 분석
고혈압 치료제 업계의 동향
밸류체인 분석
COVID-19의 영향 분석

제5장 세계의 고혈압 치료제 시장 : 병태별

주요 조사 결과
서론
1차
2차

제6장 세계의 고혈압 치료제 시장 : 유통 채널별

주요 조사 결과
서론
소매 약국
E-Commerce 약국
병원 약국

제7장 세계의 고혈압 치료제 시장 : 유형별

주요 조사 결과
서론
이뇨제
알파 차단제
칼슘채널 차단제
베타 차단제
안지오텐신 전환 효소(ACE) 저해제
혈관확장제
기타

제8장 세계의 고혈압 치료제 시장 : 치료제 유형별

주요 조사 결과
서론
병용요법
단일요법
고정용량 조합

제9장 세계의 고혈압 치료제 시장 : 지역

주요 조사 결과
서론
- 고혈압 치료제 시장 평가 : 지역별, 2019-2032년
북미
- 북미 : 병태별, 2019-2032년
- 북미 : 치료제 유형별, 2019-2032년
- 북미 : 유통 채널별, 2019-2032년
- 북미 : 유형별, 2019-2032년
- 미국
- 캐나다
유럽
- 유럽 : 병태별, 2019-2032년
- 유럽 : 치료제 유형별, 2019-2032년
- 유럽 : 유통 채널별, 2019-2032년
- 유럽 : 유형별, 2019-2032년
- 영국
- 프랑스
- 독일
- 이탈리아
- 스페인
- 네덜란드
- 러시아
아시아태평양
- 아시아태평양 : 병태별, 2019-2032년
- 아시아태평양 : 치료제 유형별, 2019-2032년
- 아시아태평양 : 유통 채널별, 2019-2032년
- 아시아태평양 : 유형별, 2019-2032년
- 중국
- 인도
- 일본
- 말레이시아
- 인도네시아
- 한국
중동 및 아프리카
- 중동 및 아프리카 : 병태별, 2019-2032년
- 중동 및 아프리카 : 치료제 유형별, 2019-2032년
- 중동 및 아프리카 : 유통 채널별, 2019-2032년
- 중동 및 아프리카 : 유형별, 2019-2032년
- 사우디아라비아
- 남아프리카공화국
- 이스라엘
- 아랍에미리트
라틴아메리카
- 라틴아메리카 : 병태별, 2019-2032년
- 라틴아메리카 : 치료제 유형별, 2019-2032년
- 라틴아메리카 : 유통 채널별, 2019-2032년
- 라틴아메리카 : 유형별, 2019-2032년
- 멕시코
- 브라질
- 아르헨티나

제10장 경쟁 구도

확대와 인수 분석
- 확대
- 인수
제휴/협업/합의/공개

제11장 기업 개요

Takeda Pharmaceutical Company Limited
AstraZeneca
Teva Pharmaceutical Industries Ltd
Abbott
Pfizer Inc
Novartis AG
Merck KGaA
Johnson & Johnson Services, Inc
Gilead Sciences, Inc
Sanofi S.A
Bayer AG

KSA 24.07.12

The global hypertension drug market size is expected to reach USD 34,646.10 Million by 2032, according to a new study by Polaris Market Research. The report "Hypertension Drug Market Share, Size, Trends, Industry Analysis Report, By Condition (Primary, Secondary); By Type; By Propulsion; By Distribution Channel; By Medication Type; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The hypertension drugs market is experiencing substantial growth, driven in part by the rising awareness of hypertension as a critical health issue and improved access to healthcare services worldwide. This trend is crucial in stimulating demand for antihypertensive medications, as increased awareness and healthcare access directly influence the diagnosis and management of hypertension, a major risk factor for cardiovascular diseases.

Awareness of hypertension, often referred to as high blood pressure, has significantly increased among the general population and healthcare professionals. This heightened awareness is the result of extensive public health campaigns, educational programs, and initiatives by governments and non-governmental organizations aimed at combating cardiovascular diseases. These efforts have made individuals more cognizant of the risks associated with high blood pressure, including stroke, heart attack, and kidney failure, thereby encouraging proactive management of blood pressure levels. As awareness grows, more individuals are likely to seek medical advice for hypertension, directly impacting the demand for antihypertensive drugs.

The role of healthcare access in driving the hypertension drugs market cannot be overstated. In recent years, there has been a global push towards improving healthcare infrastructure, particularly in developing countries. This includes the expansion of healthcare facilities, increased availability of healthcare professionals, and the implementation of universal health coverage schemes. Such developments have made healthcare services more accessible to a larger segment of the population, thereby increasing the likelihood of hypertension diagnosis and treatment. Early and effective management of hypertension significantly reduces the risk of developing severe complications, necessitating the use of antihypertensive medications.

Telemedicine and digital health platforms have also played a pivotal role in enhancing healthcare access. These technologies have made it possible for patients in remote or underserved areas to consult with healthcare providers, receive health education, and manage chronic conditions like hypertension. The convenience and efficiency of telehealth services have led to wider adoption of these platforms, further driving the demand for hypertension medications as more individuals receive timely diagnoses and prescriptions.

Moreover, the integration of hypertension management into primary healthcare settings has been a significant factor in improving healthcare access. Primary care practitioners are often the first point of contact for individuals with health concerns, making them instrumental in the early detection and management of hypertension. By integrating blood pressure screening into routine healthcare visits, healthcare systems can identify and treat hypertension more effectively, thereby increasing the demand for antihypertensive medications.

The global burden of hypertension is a pressing public health challenge, with the condition being a major contributor to the global disease burden. As societies become more informed about the implications of uncontrolled blood pressure and as healthcare systems evolve to become more inclusive and accessible, the demand for hypertension drugs is expected to rise. The growing emphasis on preventive healthcare and the management of chronic conditions further underscores the need for effective antihypertensive medications.

Hypertension Drug Market Report Highlights

In 2023, the angiotensin-converting enzyme (A.C.E.) inhibitors segment accounted for the largest market share in the hypertension drug market. Their efficacy in the long-term management of hypertension without significant adverse effects makes them a preferred choice for chronic therapy.

The retail pharmacies segment is expected to grow at the fastest CAGR during the forecast period. Retail pharmacies increasingly offer services such as blood pressure monitoring, health screenings, and chronic disease management programs, making them a key point of contact for hypertension patients.

In 2023, North America dominated the largest market. The aging population in North America significantly contributes to the hypertension drug market. Hypertension prevalence increases with age, and the U.S. Census Bureau projects that by 2030, all baby boomers will be age 65 or older, further increasing the demand for hypertension medications.

Asia Pacific is expected to grow at the fastest CAGR in Hypertension Drug market. Economic Growth and Rising Healthcare Expenditure: Economic growth in many Asia Pacific countries has led to increased healthcare expenditure. This allows for greater investment in healthcare infrastructure and access to a wider range of medications, including those for hypertension.

The global key market players are Takeda Pharmaceutical Company Limited., AstraZeneca, Teva Pharmaceutical Industries Ltd, Abbott, Pfizer Inc., Novartis AG, Merck KGaA, Johnson & Johnson Services, Inc., Gilead Sciences, Inc., Sanofi S.A., Bayer AG.

Polaris Market Research has segmented the hypertension drug market repair report based on condition, type, distribution channel, medication type, and region.

Hypertension Drug, Condition Outlook (Revenue - USD Million, 2019 - 2032)

Primary
Secondary

Hypertension Drug, Type Outlook (Revenue - USD Million, 2019 - 2032)

Diuretics
Alpha-Blockers
Calcium Channel Blockers
Beta blockers
Angiotensin-Converting Enzyme (A.C.E.) Inhibitors
Vasodilators
Others

Hypertension Drug, Distribution Channel Outlook (Revenue - USD Million, 2019 - 2032)

Retail Pharmacies
E-Commerce Pharmacies
Hospital Pharmacies

Hypertension Drug, Medication Type Outlook (Revenue - USD Million, 2019 - 2032)

Combination Therapy
Monotherapy
Fixed Dose Combinations

Hypertension Drug, Regional Outlook (Revenue - USD Million, 2019 - 2032)

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
Russia
Netherlands
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Indonesia
Malaysia
Australia
Rest of Asia Pacific
Latin America
Argentina
Brazil
Mexico
Rest of Latin America
Middle East & Africa
UAE
Saudi Arabia
Israel
South Africa
Rest of Middle East & Africa

1. Introduction

1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
1.2. Stakeholders

2. Executive Summary

2.1. Market Highlights

3. Research Methodology

3.1. Overview
- 3.1.1. Data Mining
3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources

4. Global Hypertension Drug Market Insights

4.1. Hypertension Drug - Industry Snapshot
4.2. Hypertension Drug Market Dynamics
- 4.2.1. Drivers and Opportunities
  - 4.2.1.1. Increasing prevalence of hypertension worldwide have been projected to spur drug demand
  - 4.2.1.2. Rising awareness of hypertension as a critical health issue and improved access to healthcare services
- 4.2.2. Restraints and Challenges
  - 4.2.2.1. Patent expirations
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
4.4. PESTLE Analysis
4.5. Hypertension Drug Industry Trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis

5. Global Hypertension Drug Market, by Condition

5.1. Key Findings
5.2. Introduction
- 5.2.1. Global Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
5.3. Primary
- 5.3.1. Global Hypertension Drug Market, by Primary, by Region, 2019-2032 (USD Million)
5.4. Secondary
- 5.4.1. Global Hypertension Drug Market, by Secondary, by Region, 2019-2032 (USD Million)

6. Global Hypertension Drug Market, by Distribution Channel

6.1. Key Findings
6.2. Introduction
- 6.2.1. Global Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
6.3. Retail Pharmacies
- 6.3.1. Global Hypertension Drug Market, by Retail Pharmacies, by Region, 2019-2032 (USD Million)
6.4. E-Commerce Pharmacies
- 6.4.1. Global Hypertension Drug Market, by E-Commerce Pharmacies, by Region, 2019-2032 (USD Million)
6.5. Hospital Pharmacies
- 6.5.1. Global Hypertension Drug Market, by Hospital Pharmacies, by Region, 2019-2032 (USD Million)

7. Global Hypertension Drug Market, by Type

7.1. Key Findings
7.2. Introduction
- 7.2.1. Global Hypertension Drug Market, by Type, 2019-2032 (USD Million)
7.3. Diuretics
- 7.3.1. Global Hypertension Drug Market, by Diuretics, by Region, 2019-2032 (USD Million)
7.4. Alpha-Blockers
- 7.4.1. Global Hypertension Drug Market, by Alpha-Blockers, by Region, 2019-2032 (USD Million)
7.5. Calcium Channel Blockers
- 7.5.1. Global Hypertension Drug Market, by Calcium Channel Blockers, by Region, 2019-2032 (USD Million)
7.6. Beta blockers
- 7.6.1. Global Hypertension Drug Market, by Beta blockers, by Region, 2019-2032 (USD Million)
7.7. Angiotensin-Converting Enzyme (A.C.E.) Inhibitors
- 7.7.1. Global Hypertension Drug Market, by Angiotensin-Converting Enzyme (A.C.E.) Inhibitors, by Region, 2019-2032 (USD Million)
7.8. Vasodilators
- 7.8.1. Global Hypertension Drug Market, by Vasodilators, by Region, 2019-2032 (USD Million)
7.9. Others
- 7.9.1. Global Other Hypertension Drug Market, by Region, 2019-2032 (USD Million)

8. Global Hypertension Drug Market, by Medication Type

8.1. Key Findings
8.2. Introduction
- 8.2.1. Global Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
8.3. Combination Therapy
- 8.3.1. Global Hypertension Drug Market, by Combination Therapy, by Region, 2019-2032 (USD Million)
8.4. Monotherapy
- 8.4.1. Global Hypertension Drug Market, by Monotherapy, by Region, 2019-2032 (USD Million)
8.5. Fixed Dose Combinations
- 8.5.1. Global Hypertension Drug Market, by Fixed Dose Combinations, by Region, 2019-2032 (USD Million)

9. Global Hypertension Drug Market, by Geography

9.1. Key findings
9.2. Introduction
- 9.2.1. Hypertension Drug Market Assessment, By Geography, 2019-2032 (USD Million)
9.3. Hypertension Drug Market - North America
- 9.3.1. North America: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
- 9.3.2. North America: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
- 9.3.3. North America: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
- 9.3.4. North America: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
- 9.3.5. Hypertension Drug Market - U.S.
  - 9.3.5.1. U.S.: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
  - 9.3.5.2. U.S.: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
  - 9.3.5.3. U.S.: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
  - 9.3.5.4. U.S.: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
- 9.3.6. Hypertension Drug Market - Canada
  - 9.3.6.1. Canada: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
  - 9.3.6.2. Canada: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
  - 9.3.6.3. Canada: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
  - 9.3.6.4. Canada: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
9.4. Hypertension Drug Market - Europe
- 9.4.1. Europe: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
- 9.4.2. Europe: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
- 9.4.3. Europe: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
- 9.4.4. Europe: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
- 9.4.5. Hypertension Drug Market - UK
  - 9.4.5.1. UK: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
  - 9.4.5.2. UK: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
  - 9.4.5.3. UK: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
  - 9.4.5.4. UK: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
- 9.4.6. Hypertension Drug Market - France
  - 9.4.6.1. France: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
  - 9.4.6.2. France: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
  - 9.4.6.3. France: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
  - 9.4.6.4. France: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
- 9.4.7. Hypertension Drug Market - Germany
  - 9.4.7.1. Germany: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
  - 9.4.7.2. Germany: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
  - 9.4.7.3. Germany: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
  - 9.4.7.4. Germany: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
- 9.4.8. Hypertension Drug Market - Italy
  - 9.4.8.1. Italy: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
  - 9.4.8.2. Italy: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
  - 9.4.8.3. Italy: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
  - 9.4.8.4. Italy: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
- 9.4.9. Hypertension Drug Market - Spain
  - 9.4.9.1. Spain: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
  - 9.4.9.2. Spain: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
  - 9.4.9.3. Spain: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
  - 9.4.9.4. Spain: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
- 9.4.10. Hypertension Drug Market - Netherlands
  - 9.4.10.1. Netherlands: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
  - 9.4.10.2. Netherlands: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
  - 9.4.10.3. Netherlands: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
  - 9.4.10.4. Netherlands: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
- 9.4.11. Hypertension Drug Market - Russia
  - 9.4.11.1. Russia: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
  - 9.4.11.2. Russia.: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
  - 9.4.11.3. Russia: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
  - 9.4.11.4. Russia: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
9.5. Hypertension Drug Market - Asia Pacific
- 9.5.1. Asia Pacific: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
- 9.5.2. Asia Pacific: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
- 9.5.3. Asia Pacific: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
- 9.5.4. Asia Pacific: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
- 9.5.5. Hypertension Drug Market - China
  - 9.5.5.1. China: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
  - 9.5.5.2. China.: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
  - 9.5.5.3. China: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
  - 9.5.5.4. China: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
- 9.5.6. Hypertension Drug Market - India
  - 9.5.6.1. India: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
  - 9.5.6.2. India.: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
  - 9.5.6.3. India: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
  - 9.5.6.4. India: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
- 9.5.7. Hypertension Drug Market - Japan
  - 9.5.7.1. Japan: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
  - 9.5.7.2. Japan.: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
  - 9.5.7.3. Japan: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
  - 9.5.7.4. Japan: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
- 9.5.8. Hypertension Drug Market - Malaysia
  - 9.5.8.1. Malaysia: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
  - 9.5.8.2. Malaysia.: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
  - 9.5.8.3. Malaysia: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
  - 9.5.8.4. Malaysia: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
- 9.5.9. Hypertension Drug Market - Indonesia
  - 9.5.9.1. Indonesia: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
  - 9.5.9.2. Indonesia.: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
  - 9.5.9.3. Indonesia: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
  - 9.5.9.4. Indonesia: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
- 9.5.10. Hypertension Drug Market - South Korea
  - 9.5.10.1. South Korea: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
  - 9.5.10.2. South Korea.: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
  - 9.5.10.3. South Korea: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
  - 9.5.10.4. South Korea: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
9.6. Hypertension Drug Market - Middle East & Africa
- 9.6.1. Middle East & Africa: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
- 9.6.2. Middle East & Africa: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
- 9.6.3. Middle East & Africa: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
- 9.6.4. Middle East & Africa: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
- 9.6.5. Hypertension Drug Market - Saudi Arabia
  - 9.6.5.1. Saudi Arabia: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
  - 9.6.5.2. Saudi Arabia: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
  - 9.6.5.3. Saudi Arabia: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
  - 9.6.5.4. Saudi Arabia: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
- 9.6.6. Hypertension Drug Market - South Africa
  - 9.6.6.1. South Africa: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
  - 9.6.6.2. South Africa: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
  - 9.6.6.3. South Africa: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
  - 9.6.6.4. South Africa: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
- 9.6.7. Hypertension Drug Market - Israel
  - 9.6.7.1. Israel: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
  - 9.6.7.2. Israel: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
  - 9.6.7.3. Israel: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
  - 9.6.7.4. Israel: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
- 9.6.8. Hypertension Drug Market - UAE
  - 9.6.8.1. UAE: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
  - 9.6.8.2. UAE: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
  - 9.6.8.3. UAE: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
  - 9.6.8.4. UAE: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
9.7. Hypertension Drug Market - Latin America
- 9.7.1. Latin America: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
- 9.7.2. Latin America: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
- 9.7.3. Latin America: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
- 9.7.4. Latin America: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
- 9.7.5. Hypertension Drug Market - Mexico
  - 9.7.5.1. Mexico: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
  - 9.7.5.2. Mexico: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
  - 9.7.5.3. Mexico: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
  - 9.7.5.4. Mexico: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
- 9.7.6. Hypertension Drug Market - Brazil
  - 9.7.6.1. Brazil: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
  - 9.7.6.2. Brazil: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
  - 9.7.6.3. Brazil: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
  - 9.7.6.4. Brazil: Hypertension Drug Market, by Type, 2019-2032 (USD Million)
- 9.7.7. Hypertension Drug Market - Argentina
  - 9.7.7.1. Argentina: Hypertension Drug Market, by Condition, 2019-2032 (USD Million)
  - 9.7.7.2. Argentina: Hypertension Drug Market, by Medication Type, 2019-2032 (USD Million)
  - 9.7.7.3. Argentina: Hypertension Drug Market, by Distribution Channel, 2019-2032 (USD Million)
  - 9.7.7.4. Argentina: Hypertension Drug Market, by Type, 2019-2032 (USD Million)

10. Competitive Landscape

10.1. Expansion and Acquisition Analysis
- 10.1.1. Expansion
- 10.1.2. Acquisitions
10.2. Partnerships/Collaborations/Agreements/Exhibitions

11. Company Profiles

11.1. Takeda Pharmaceutical Company Limited
- 11.1.1. Company Overview
- 11.1.2. Financial Performance
- 11.1.3. Product Benchmarking
- 11.1.4. Recent Development
11.2. AstraZeneca
- 11.2.1. Company Overview
- 11.2.2. Financial Performance
- 11.2.3. Product Benchmarking
- 11.2.4. Recent Development
11.3. Teva Pharmaceutical Industries Ltd
- 11.3.1. Company Overview
- 11.3.2. Financial Performance
- 11.3.3. Product Benchmarking
- 11.3.4. Recent Development
11.4. Abbott
- 11.4.1. Company Overview
- 11.4.2. Financial Performance
- 11.4.3. Product Benchmarking
- 11.4.4. Recent Development
11.5. Pfizer Inc
- 11.5.1. Company Overview
- 11.5.2. Financial Performance
- 11.5.3. Product Benchmarking
- 11.5.4. Recent Development
11.6. Novartis AG
- 11.6.1. Company Overview
- 11.6.2. Financial Performance
- 11.6.3. Product Benchmarking
- 11.6.4. Recent Development
11.7. Merck KGaA
- 11.7.1. Company Overview
- 11.7.2. Financial Performance
- 11.7.3. Product Benchmarking
- 11.7.4. Recent Development
11.8. Johnson & Johnson Services, Inc
- 11.8.1. Company Overview
- 11.8.2. Financial Performance
- 11.8.3. Product Benchmarking
- 11.8.4. Recent Development
11.9. Gilead Sciences, Inc
- 11.9.1. Company Overview
- 11.9.2. Financial Performance
- 11.9.3. Product Benchmarking
- 11.9.4. Recent Development
11.10. Sanofi S.A
- 11.10.1. Company Overview
- 11.10.2. Financial Performance
- 11.10.3. Product Benchmarking
- 11.10.4. Recent Development
11.11. Bayer AG
- 11.11.1. Company Overview
- 11.11.2. Financial Performance
- 11.11.3. Product Benchmarking
- 11.11.4. Recent Development